Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gossypol Acetate Combined With Bevacizumab and FOLFIRI as Second-Line Therapy for Metastatic Colorectal Cancer With TP53 Mutation and LRPPRC Positivity: A Single-Center, Single-Arm Clinical Study

NCT07337551 is registered in ClinicalTrials.gov with Guiying Wang as lead sponsor.

NCT NCT07337551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07337551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gossypol Acetate Combined With Bevacizumab and FOLFIRI as Second-Line Therapy for Metastatic Colorectal Cancer With TP53 Mutation and LRPPRC Positivity: A Single-Center, Single-Arm Clinical Study
Lead sponsor
Guiying Wang
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 1, 2026
Completion date
February 1, 2028
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

patients with metastatic colorectal cancer who were tp53-mutant and lrpprc-positive and had previously failed prior first-line treatment